Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 11/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833884 | 0.87 | IL1B (0.55) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL30833975 | 0.87 | IL1B (0.55) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL22654864 | 0.85 | IL1B (0.66) | IL1BNLRP3 | |
| SCHEMBL22654862 | 0.85 | IL1B (0.66) | IL1BNLRP3 | |
| SCHEMBL30517832 | 0.83 | NLRP3 (0.57) | IL1BNLRP3KCNH2TNFCAMK2D | |
| SCHEMBL25519368 | 0.83 | NLRP3 (0.57) | IL1BNLRP3KCNH2TNFCAMK2D | |
| SCHEMBL29270330 | 0.82 | NLRP3 (0.57) | IL1BNLRP3KCNH2CAMK2D | |
| SCHEMBL31021469 | 0.81 | NLRP3 (0.48) | IL1BNLRP3KCNH2TNFCAMK2D | |
| SCHEMBL25798971 | 0.81 | IL1B (0.51) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL30665802 | 0.79 | IL1B (0.49) | IL1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| CN-119300833-A | Novel compounds | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118265701-A | Pyridazine derivatives as inhibitors of NLRP3 | 豪夫迈·罗氏有限公司 | 2024-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, PYCARD | IL1B 8/4885NLRP3 1/4885KCNH2 867/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | IL1B 2984/4885NLRP3 3745/4885KCNH2 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.